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SUMMARY
Nowadays, in genomocentric era accelerated research of the human genome coupled with advances is enabling the comprehensive 
molecular profiling of human tissue. Particularly, DNA microarrays are powerful tools for obtaining global view of human non-Hodgkin 
lymphomas gene expression. Complex information from lymphomas “expression profiling” studies can, in turn, be used to create 
molecular markers that have diagnostic or prognostic implications. The gene „expression profiling” is not of routine clinical oncology 
practice, but is used in genomic classification of clinically relevant subgroups of non-Hodgkin lymphoma. The genomics biomarkers 
have been incorporated into current prognostic models which are based on IPI, R-IPI, and FLIPI. Molecular or pharmacogenomic 
profiling can be used as new therapeutic targets for patients who are refractory to current therapy. We discus the utility of DNA micro-
array-based lymphoma profiling in clinical oncology research, and identify future of research in lymphoma evolving fields. 
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Introduction
Nowadays, in the genomocentric era, research of the human genome using 
microarray technology is accelerated. Genomics is comprehensive study of 
the whole genome, genetics products, and their interactions (l,2). The human 
genome consists of roughly 3 billion basepairs, and current estimate of the 
total number of genes varies from 20,000 to 25,000 but around 75% genomes 
contain so-called intergenic DNA or non-coding sequences (l,3). The interna-
tional Human Map Project identifies the variations in the sequences that are 
common among humans. The Cancer Genome Atlas (CGA) is a project to 
determine all genomic changes involved in all types of human cancer (2,3).
Non-Hodgkin lymphoma (NHL) is a heterogeneous, complex, and progressive 
clonal expansion of B-, T-lymphocytes and rarely NK-cells or their precursors 
(4). Our taxonomy of lymphomas, which is based mostly on histopathology 
and  immunophenotyping,  includes  about  30  distinct  entities  arising  from 
diverse cells types. The genetic complexity of lymphomas probably explains 
the clinical diversity with traditional methods and genomic expression analy-
sis. Microarrays technique is effective in deciphering this clinical diversity. A 
number of published studies identify gene expression signatures for major 
non-Hodgkin lymphoma types and subtypes, and uncover gene expression 
patterns that correlate with various characteristics of non-Hodgkin lymphoma 
(4). Microarrays technology  identifies molecular profile of individual tumors 
at the DNA, RNA, and protein levels. For analysis to gene expression profiling 
to classify NHLs unsupervised and supervised methods are used (5). The 
Microarray Gene Expression Data Society (www.megd.org) recommends the 
use of set of criteria (Minimum Information About a Microarray Experiment) 
(6). There are six major data bases of publicly available information: Gene 
Bank, EMBL, GEO, NCBI at NIH, DNA Data Bank of Japan, and HuGENet (7).
The era of molecular diagnostics of lymphoma started with the cloning of the 
immunoglobulin and TCR genes.  Later on, a dramatic progress in the devel-
opment of microarray technology has led to better understanding of pathogen-
esis and biology of NHLs. A number of molecular abnormalities or markers 
have been identified that have significant diagnostic or prognostic implications 
(8). Patrick O Brown published in 1995 the first paper about microarray, which 
is commonly called a “DNA-or RNA-chip” and Alizadeh et al., in 1999 and 
2000 identified three subgroups of  diffuse large B-cell lymphoma by using 
“lymphochip”. Nowadays, cDNA and oligonucleotide microarrays platforms 
are to identify more subtypes non-Hodgkin lymphoma (8).
Expression microarray technology
A DNA microarray is a miniature system containing cDNA fragments that are 
synthesized directly or spotted on glass or other matrix. Microarrays have 
been used extensively to simultaneously monitor the expression of thousands 
of genes from particular tissue or cell type. The technological progress of 
the  cDNA  microarrays  was  extremely  rapid  and  nowadays  there  are  two 
most  commonly  used  microarray  systems  complementary  DNA  (cDNA) 
and oligonucleotide arrays, which differ in probe materials. The cDNA array 
probes are usually products of the PCR, generated from cDNA libraries or 
clone collections  and contain from 500 to 5000 bp cDNA (9). These probes 
are printed on glass slides or nylon membranes as spots at defined locations, 
typically 100-300 μm. The benefit of spotted arrays is that they can be made 
by individual investigators and do not require a priori knowledge of cDNA 
sequences (5,9). The oligonucleotide microarrays can be manufactured by 
various methods: in situ synthesis method for high-density oligonucleotide 
arrays used by Affimetrix and Agilent Technologies, and the contact (pins) 
and  non-contact  (ink-jet)  printing  methods  of  presynthesized  oligonucle-
otide probes. The in  situ synthesis is a powerful method: the process can 
achieve extremely high spot densities (spot size of 5 μm in 2005) and the 
probe sequence can be chosen more or less randomly for each synthesis. 
Oligonucleotides offer greater specificity than cDNAs because they can by 
tailored to minimize chances of cross-hybridization. Sequences up to 25-70 
bp nucleotides have been used effectively. Major advantages of this assays 
is uniformity of probe length and the ability to discern splice variants (9). The 
data analysis of microarray experiment is a multi-step and complex process 
which contains: image analysis, signal adjustment and data normalization. 
Image analysis software is used to calculate the intensity of each spot or 
probe on the array and to store these measurements as numerical values in 
the text file. For statistical analysis and visualization of gene expression data 
a large number of commercial and non-commercial software tools have been 
developed (e.g., Gene Spring, Gene Cluster, Cluster, and Treevoew, SAM and d 
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CHIP) (9). For classification gene expression data used unsupervised cluster-
ing or class discovery and supervised clustering or class prediction methods. 
The expression data can be pictorially summarized, where each row repre-
sents single gene, and each column represents expression levels. (7,9). A 
supervised analysis requires the grouping of patients according to predefined 
characteristics. In the unsupervised clustering  analysis genes or samples are 
grouped into classes on the basis of the similarity in their expression profiles 
across cases, tissues or conditions.  Microarray analyses are used in clinical 
oncology: to identify altered genes or biochemical pathways, to identify new 
class of disease, to predict diagnosis, and classification of unknown samples 
(10). Microarray technology has a number of limitations (volume tissue, the 
search for differently expression genes, and statistical analysis) (5,11). 
The basic concept of microarray technology is to hybridize preprocessed 
sequences  of  mRNA  (targets)  to  the  complementary  sequences  (probes) 
bound to a solid surface, and to quantify the amount of specifically hybridized 
target,  typically  by  fluorescence  two-color  or  one-color  detection  system 
(Figure 1) (3,11).
Figure 1. Schematic illustration of DNA microarray analysis.
Source: http://genome.gov/10000533
(Courtesy: National Human Genome Research Institute)
Gene expression profiling in diffuse large B-cell 
lymphoma 
Primary diffuse large B-cell lymphoma (DLB-CL) is an aggressive malignancy 
of mature B-lymphocytes and the most common subtype of non-Hodgkin 
lymphoma in adults. It account for  30% to 40% of all newly diagnosed cases 
and more than 80% of aggressive lymphomas (12,13). DLB-CL is commonly 
composed of centrobalst-like and immunoblast-like cells. These cells express 
the B-cell markers: CD19, CD20, and CD22, and sIg. The approximately 50% 
of DLB-CL is characterized by chromosomal translocation: t(3;14), t(8;14), 
and t(14;18). These translocations deregulate expression of Bcl-6(3q21), myc 
(8q24), and Bcl-2(18q21) genes, as a result of their juxtaposition to the Ig 
genes (14). DLB-CL represents a heterogeneous entity of a variety of molecular 
aberration, some of which have been shown to be predicative of outcome. The 
most frequently aberrations are: p53, myc, rel, Bcl-6, p16, p38MAPK, FLK1, 
CDK2 chromosomal deletion BLIMP1, and aberrant somatic hypermutation 
PIM1, PAX5, and Rho. The delBLIMP1 locus on chromosome 6q21q22.1 is 
frequently identified in ABC-DLB-CL signature, but not in GBC or type 3 DLB-
CL signature (15). In DLB-CL the Ig variable region genes commonly undergo 
somatic  mutations.  The  CD44v6  is  expressed  predominantly  in  advanced 
disease  stage  and  in  ABC-DLB-CL  in  CD44  negative  cases.  The  CD44v6 
expression is associated with poor prognosis (16). Iqbal et al., identified in the 
GCB-DLB-CL translocation t(14;18) group with positive and negative subsets. 
The translocation t(14;18) was detected in 20% of DLB-CL (17).
Table1. Molecular subtypes of DLB-CL
GCB ABC PMBCL
Median age, year 58 66 25
Age older than 60 year, % 52 66 9
Female, % 50 40 70
Female younger than 35 year, % 3 2 35
5-year survival 59 30 64
Source: Armitage JO (ref. 18)
At the present time, gene expression profiling is not of routine clinical oncol-
ogy  practice,  but  it  used  in  molecular  classification  of  clinically  relevant 
subgroups  of  DLB-CL  (Table  1)  (18).  The  genomic  markers  have  been 
incorporated into current prognostic models which are based on International 
Prognostic Index (IPI,R-IPI). It contains risk factors significant for the prog-
nosis of overall survival (age, stage, sLDH, performance status, and number 
of extranodal disease sites) and  has been used to stratify patients in risk of 
treatment failure (19,20). Subclassification of DLB-CL was done by tissue 
specific microarrays and selected into prognostic subgroups based on cellular 
origin: germinal center B-cell –like (GCB-like), activated B-cell like (ABC-like), 
and type 3 or primary mediastinal B-cell lymphoma (PMBL) (21) The DLB-CL 
subgroups are distinguished from each other by the differential  expression 
of hundreds of different genes, and these genes relate to each subgroup 
to separate stage of B cell differentiation and activation. These molecular 
differences suggest that DLB-CL subgroups (GBC, ABC, and PMBL) should 
be  considered  as  separate  diseases  (21).  Patients  with  gene  expression 
profiling of GCB have a significantly better survival than the patients with gene 
expression profiling of ABC. The type 3 has a poor clinical outcome which is 
similar to the ABC subgroup (Figure 2). Alizadeh et al., created a “fuzzy neural 
network” for the precise prediction of survival of patients with DLB-CL. In this 
model four genes are identified (CDIU, AA800/551, AA805661, and IRF4) 
that could be used to predict prognosis with 93% accuracy. The average 5 
years overall survival for all patients was 52%, 76% of GCB-like, and 16% of 
ABC-like DLB-CL patients (21).
Patients with low expression CD10 have a poor prognosis. However, patients 
with  high  CD10  and  AA807551  high  expression  and  low  expression  of 
AA805611 genes have poor prognosis (21). The gene expression profiling 
(GEP)  of  GCB  includes  many  markers  of  germinal  center  differentiation 
(e.g.CD10, CD38, A-myb, OGG1, HGAL, Bcl-6,Bcl-7A, and LMO2) (21,22).   
The ABC GEP includes genes: IREL (MUM1/LSIRF), CCND2, SYCA3, FLIP , 
Bcl-Xl, Bcl-2, BLIMP1, and XBP1, and absent expression of Bcl-6 gene.  The 
expression of Bcl-2, CCND2 and SYCA3 correlated with short survival. The 
Bcl-2 is independent marker of a poor prognosis for patients with DLB-CL. 
The expression of LMO2, Bcl-6 and lymph node signature  correlated with 
prolonged survival (Figure 2) (23). 
Rosenwald et al., showed four gene expression profiling with “17 genes” 
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correlated with overall survival after chemotherapy. Also, the GCB subgroup 
has a decreased activity of NF-kB signaling pathway. However, ABC subgroup 
has  a    constitutive  activation  of  this  pathway.  The  GCB  subgroup  had  a 
5-year  survival  rate  of  60%,  while  ABC  and  type  3  of  DLB-CL  had  35% 
and 39%, respectively. In GBC subgroup only Bcl-2 translocation and c-rel 
amplification are detected. The two genes Bcl-6 and HGAL predict overall 
survival.  However,  CD10  which  is  a  GCB  marker,  did  not  predict  overall 
survival patients in DLB-CL subgroup (Figure 2) (23).
Figure 2. Gene expressions profiling of diffuse large-B-cell lymphoma (DLB-CL). 
Panel A shows the hierarchical clustering of diffuse large-B-cell lymphomas. Panel B 
shows the number of samples with amplification of the c-rel locus and bcl-2 translo-
cations in subgroups of diffuse large-B-cell lymphoma. Panel C shows Kaplan–Meier 
estimates of overall survival after chemotherapy among the 240 previously untreated 
patients, according to the gene-expression subgroup (with permission, Rosenwald 
A, et al. The use of molecular profiling to predict survival after chemotherapy for 
diffuse large-B-cell lymphoma. N Engl J Med 2002;34:1937-47. Copyright © 2002 
Massachusetts Medical Society. All rights reserved.)
Also, Wang et al., (24) used first “self organized map” and confirmed better 
survival for patients expressing GCB profiling than other subgroups.  Shipp et 
al., (25) used the supervised method called “weighted voting algorithm” for 
distinction of DLB-CL vs. FL and prediction of survival of patients with DLB-
CL. Based on this classification they identified “cured vs. fatal/refractory” 
survival phenotype groups. The “cured” group patients had a 5-year overall 
survival of 70%, while “fatal/refractory” group had overall survival of only 
12%. In fatal/refractory DLB-CL signature overexpression of BCR, PDE4B, 
NOR1, HMGM, HCK, galectin 3, and BFL1A1 is identified. The overexpression 
of BFL1A1 is important for reducing the chemosensitivity of DLB-CL patients. 
This microarray classification is a better predictor for patients’ survival than 
IPI classification (25).
Finally, Lossos et al. (2004) identified with unsupervised analysis clinical 
prediction model for survival based on “6 strongest predictor genes” (LMO2, 
Bcl-6, FN1, CCND2, SCY3, and Bcl-2). The expression of LMO2, Bcl-6 (GBC 
signature) and FN1 correlated with prolonged survival, while the expression of 
Bcl-2, CCND2 and CCL3 (previously named SYC3-ABC signature) correlated 
with shorter survival. The identification of the overexpression of these “6 
genes” is sufficient to predict survival in DLB-CL patients (26,27). 
Wright et al., used “compound covariates” to discriminate between subtypes 
of DLB-CL (28).  Sakhinia et al.,  identified “indicator genes” (cyclin B1, 
NPM3, and COL3A1), which were higher in DLB-CL (29).
Colomo et al, and Nyman et al., demonstrated two phenotypes: GCB and non-
GCB by immunohistochemical methods with GCB markers (CD10, Bcl-6) and 
activation markers (MUM1/IRF4 and CD135) (Table 2). Patients with GCB mark-
ers had much better survival than patients with activation markers (30-33).
Table 2. The immunophenotypical profiling of the DLB-CL
GCB Bcl-2 - Bcl-6 + CD 10 +
ABC Bcl-2 + Bcl-6 - CD 10 –
PMBCL Coexpression or lack of expression of these  
three members
Source: Nyman H et al. (ref. 31)
The patients with the non-GCB phenotypes  or expression of Bcl-2 or cyclin 
D2,    demand  more  aggressive  therapies.  The  NF-kB  transcription  factors 
are highly expressed in ABC-DLB-CL, but not in GCB-DLB-CL. Because of 
this, NF-kB pathway is a potential new therapeutic target for patients with 
ABC-DLB-CL  who  are  refractory  to  current  therapies  (34).    Millennium 
Pharmaceuticals tested two beta-carboline derivates as inhibitors of the IKKs 
and inhibitors of E3 ligase complex and PKC-beta (PS 1145, PDE-4B-enza-
turin) (35,36). Deregulated cyclin E is a strong predictor of a poor prognosis 
and possible target for individualized antitumor therapy (37).
Primary mediastinal large B-cell lymphoma (PMBCL) is a special subtype 
of DLB-CL, which  originates from thymus B lymphocytes. This lymphoma 
accounts for 2% of all NHLs and histologically it is characterized by fibrosis 
(38).  Clinical  manifestation  of  PMBCL  is  similar  to  Hodgkin  disease  in 
younger patients (Table 1). Clinical course is aggressive and patients have 
shorter overall survival than those affected with other types of DLB-CL. The 
PMBCL have distinctive chromosomal aberration, but gain of  9p is specific 
for PMBCL, and observed in 75% cases. Mutations in SOCS-1 gene correlate 
with  gains of 9p24 JAK locus. Savage et al., (38) identified  a molecular 
signature unique only for PMBCL; it was termed “46 specific genes”.  PDL2is 
the  best  discriminator  of  PMBL  from  other  DLB-CL,  but  it  is  also  highly 
expressed  in  Hodgkin  lymphoma  cells  (39).  Also,  molecular  signature  of 
PMBL is characterized by the absence of rearrangement of Bcl-2 and Bcl-6 
genes and overexpression of IL-13R alfa.  A number of regulators of T-cell 
activation and downstream effectors JAK2 and STAT1 and increased expres-
sion of several genes associated with NF-kB may be the points of attack for 
future therapeutic agents (38,39).  The loss of MHCII expression is correlated 
with worse outcome in patients with PMBCL (40). 
Mircean et al.,  and Suguro M et al.,  identified de novo subgroup CD5+ 
DLBCL that expresses CD5 on the cell surface (41,42). CD5+ is expressed 
on T cells and subset of B cells. In B-cell neoplasms, CD5+ is expressed 
on CLL, MCL, DLB-CL and marginal zone of B-cell lymphoma (42).  This 
subgroup comprises 10% of all DLB-CL (negative for CD10, CD21, CD23,   
cyclin D1 and with  predominance of surface IgMkapa) and has a more 
aggressive clinical course and worse prognosis then CD5- DLB-CL (42). The 
CD5+ signature shows high levels of integrin beta 1 in lymphoma cells and 
CD36 in the vascular cells. To differentiate CD5+ subgroup from other types 
of DLB-CL  and  mantle cell lymphoma four gene groups are used: metabo-31 www.onk.ns.ac.yu/Archive   Vol 15,  no 1-2,  July 2007
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lism, signal transduction, transcription factors, cell adhesion, and migration. 
In CD5+ expression profile there is a deregulation of ECM genes (POSTN, 
COL1A1, CTSK, MMPS, and LAMB3), and upregulation of TRPM genes. The 
expression of Bcl-6 and CD10 is associated with longer overall survival, but 
expression MUM1 and cyclin D2 is associated with shorter overall survival. 
The expression Bcl-2 or FOXP1 did not predict overall survival (41,42). In 
small number of cases CD5+ signature can also be used in prognosis for 
mantle cell lymphoma but for differentiation between two gene entities cyclin 
D 1 expression should be used. 
Gene expression profiling of follicular 
lymphomas
Follicular lymphoma (FL) is heterogeneous disease which comprises 20% of 
all NHLs. About 70% FLs have indolent clinical course.  However, 10% of FLs 
may transform into DLB-CL with more aggressive clinical course. The FL is 
composed of follicular centre cells (small cells and large cells). The FLs are 
characterized with t(14;18)(q32;q21) translocation. This translocation leads 
to the deregulation of the Bcl-2 gene, with overexpression of the antiapoptotic 
Bcl-2 protein. The Bcl-2/IGH translocation is necessary, but it is not sufficient to 
cause FLs (45). The additional alteration in genes expression (IL-1, IL-8, and IL-
12B) may contribute to malignant phenotype. In transformed FLs are involved 
genes:  CXCL2,  NEK2,  MAPK1,  CD69,  DNA    polymerase,  WEE1,  HMGA1, 
ras, surviving, BIRC5, LDH, and c-myc.  FLs are positive for CD10. Clinical 
prognostic indicators IPI and FLIP (age, sLDH, stage, Hb and number of nodal 
areas) are  limited in to  low and low-intermediate risk groups. Also, classical 
morphological grading system (1,2,3a, and 3b) is not optimal for the choice of 
therapy (46). Therefore, Björck  added to FLIPI index high expression of cyclin 
B1 as independent prognostic factor which correlates with longer survival (47). 
Follicular lymphoma is immunological functional disease in which an interac-
tion between nonmalignant immune cells of the microenvironment and tumor 
cells determines the clinical behavior (48). So far, a number of gene signatures 
have been identified: “81 gene predictor signature”, “37 genes signature”, and 
“indicator genes” signature (46,48). Investigators from NCI have discovered 
two subsets of genes “survival-associated signatures named IR-l, and IR-2 
, whose expression is linked to survival advantage in patients with follicular 
lymphomas (Figure 3). The overexpression of the immune response-1(IR-1) 
signature  correlated  with  good  prognosis,  while  immune  response-2(IR-2) 
signature correlated with poor prognosis (Figure 4) (46,48,49). 
The immune response-1 signature included genes encoding T-cells markers 
(CD7, CD8B1, ITK, LEF, and STAT4, osteopontin, MRCOX2, turgen, GRO1, 
GRO2,  NKCT4,  LEU13,  IFN2,  NCF4,  CUB  C1s,  C1qr,  TCRbeta,  TCRteta, 
TNF1beta,  TNFalfa1,  JUNB,  FOSGA-beta,  p75NTR)  and  genes  that  are 
highly expressed in macrophages (ACTN1, and TNFRF13B). However, the 
immune  response-2  signature  included  genes  known  to  be  preferentially 
expressed in macrophages, dendritic cells or both (TLR5, FCCR1A, SEP1o, 
LOM,  and  CAR1)  (46).  The  FLs  signature  contains  genes  upregulated  in 
aggressive phase disease that are involved in cell cycle (CCNE2, CCNA2, 
CDK2,  CHEK1,  MCM7)  and  DNA  synthesis  (TOP2A,  POLO3A,  HMGA1, 
POLE2, GMPS, CTPS); genes which reflected increased metabolism (FRSB, 
RARS, HK2, LDH2); genes involved in signal transduction (FR2B, HCFCR1, 
PIK4CA, MAPK1) and genes derived from the reactive infiltrate of T cells and 
macrophages (CD3D, CXCLI2, TM4SF2) (46). Also, CD68 is an independent 
predictor overall survival. Patients with 15 or more CD68 macrophages per 
high power filed had a better overall survival than patients with less from 15 
CD68  positive  macrophages  (46).  For  distinction  DLB-CL  from  FLs  used 
“indicator genes” signatures. In this signatures high levels YY1 gene were 
associated  with  shorter  survival  in  FLs  and  DLB-CL  (19,46,49).  Besides 
these complex genomic profiles individual gene markers are also used in the 
survival prognosis of patients with FLs (49). The FLs genomic expression 
profile is essential to guide the choice of therapy.
Figure 4. Survival patients of follicular lymphoma based on the immune-response gene expression signature. Panel 
A shows overall survival according to the survival-predictor score (SPS). Panel B shows overall survival according 
to the IPI risk group. Panel C shows overall survival among the patients (IPI) stratified according the quartile of the 
SPS. (with permission, Dave SS, et al. Prediction of survival in follicular lymphoma based on molecular features of 
tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-9. Copyright © 2004 Massachusetts Medical Society. 
All rights reserved.)
Figure 3. Genomic expression profiling of follicular lymphoma (with permission, Dave SS, et al. Prediction of survival in 
follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-9. 
Copyright © 2004 Massachusetts Medical Society. All rights reserved.)32 www.onk.ns.ac.yu/Archive   Vol 15,  no 1-2,  July 2007
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Gene expression of Burkitt’s lymphoma
Burkitt’s lymphoma (BL) is a rare and aggressive B-cell lymphoma character-
ized by a high degree of proliferation of the malignant cells and deregulation 
of the c-myc gene (1900800) and their kappa and lambda chain IG genes 
(147200,147200). In 5% to 10% of DLB-CL cases are overlapping in morpho-
logical and immunophenotypic features with Burkitt’s lymphoma (50). Dave et 
al., and Hummel et al., identified a characteristic genetic signature that clearly 
distinguishes this tumor from of DLB-CL (50,51).  The “core-group extension 
strategy” is based on the NSC method by which 58 genes that constitute the 
molecular Burkitt’s lymphoma (mBL) signature have been identified. Some of 
them belong to NF-kB (e.g. BL2A1, FLIP , CD44, NF-kB1A, Bcl-3 and STAT 3) 
and serve to differentiate between two subgroups GBC and ABC DLB-CL (51). 
Based on microarray analysis three major cytogenetic groups are identified: 
“myc simple, myc complex, and myc negative” (Table 3).
Table 3. Molecular classification Burkitt’s lymphoma
Type Molecular characterization
Clinical 
outcome
Survival
5-year,%
”Myc simple”
IG-myc fusion and low 
 Chromosomal complexity,                                                                                                       
Score<6
Favorable 76
”Myc complex”
non-IG-myc fusion or IG-myc 
Fusion and a high chromosomal                                                                                                       
Complex, score>6
Poor 21
”Myc negative”                                                           
Comprising myc-negative                                                                                                       
lymphoma
Source: Hummel M et al. (ref. 51)
Patients with mBL had a favorable prognosis with 5-year survival rate of 75% 
(Figure 5).
Figure 5. Overall survival patients of Burkitt’s lymphoma (with permission, Hummel 
B, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic 
profiling.  N  Engl  J  Med  200;354:2419-30.  Copyright  ©  200  Massachusetts 
Medical Society. All rights reserved.)
The presence of breakpoint of the myc focus is strongly associated with 
unfavorable prognosis, as compared with the absence of such breakpoint 
(15% vs. 44%). About 46% cases with IG-myc and non-IG-myc breakpoint 
had concurrent Bcl-2 and Bcl-6 translocation (52).  “The value of molecular 
profiling to accurately diagnostic Burkitt’s lymphoma versus DLBCL will have 
a major impact on patients because the treatment for these two lymphomas 
is very different. If Burkitt’s patients are treated with intensive therapy, there is 
roughly an 80% survival rate. However, if they are misdiagnosed with DLBCL, 
and treated with lower intensity chemotherapy, the survival rate is reversed to 
20% or even less” (53).
Gene expression of Mantle cell lymphoma
Mantle cell lymphoma (MCL) is aggressive type of NHL and comprises about 
6% of all NHLs. MCL has worse prognosis with survival about 3 to 4 years 
(54,55). Mantle cell lymphoma is a specific subtype of NHLs derived from 
naive CD5+ cells residing in the pregerminal center of primary follicles or 
mantle zones of secondary follicles (56). MCL is a prototypical neoplastic 
disease  in  which  a  common  cytogentic  t(11;14)  translocation  leading  to 
cyclin D1 overexpression is associated with other changes of the clinical, 
morphological, and molecular variable of this disease. High levels of cyclin 
D1 are associated with greater proliferation and with poorer survival. The 
determination of these abnormalities is important for a diagnosis of MCL. 
Another gene, ATM, which encoding nuclear phosphoproprotein from 370kD 
plays  role  in  DNA  repair  and  cell  cycle  control,  is  frequently  mutated  on 
points: ink 2418-19, E2236FS, E423 (55).  In addition to these deregula-
tions, alterations have been also identified: deletion CDK, amplification CDK4, 
transcription repression p16/ink4a, overexpression of BLM-1, deregulation 
cell cycle and NF-kB pathways, PI3/AKT, and SYK kinases (57,58).  With a 
cDNA microarray specific “MCL signature with 446 genes” has been identified 
in MCL. These genes include: genes involved in apoptosis, cell cycle, signal 
transduction, and cell structure. Also, identified are alterations in TNF and 
NF-kB pathways; overexpression of IL10R, SPARC, osteopontin and BM40 
genes; somatic mutation in IGVH and CDC14A, ras,  and other genes (59).   
This characteristic GEP identifies a new subgroup that is cyclin Dl negative. 
GEP signature is also defined for blastoid variant (BV) that is refractory to con-
ventional chemotherapy and associated with a very poor prognosis (60).  The 
GEP MCL-BV increased number of genomic gains and deletions of p16ink4a 
and p53 genes correlated with poorer clinical outcomes, while 1p21 loss and 
IGBH mutation were associated with prolonged survival (61).  In this signature 
were identified: gain of TOP1, loss of caspase 7 and RAB27A, and increase 
of CDK4, IL14alfa (61,62). Also, in MCL-BV were identified overexpression of 
CD28, B-myb, PIM1, PIM2, DAD1, RSK1, and YY1.  The patients with cyclin 
D1 positive signature and deletion p16/ink4a are associated with the worst 
clinical outcome (63,64). 
Gene expression of T-cell lymphoma
Peripheral T-cell lymphoma (PTCL) represents about 12% of NHLs. PTCL is het-
erogeneous group of lymphoma which cannot be classified on basis of morphol-
ogy or conventional molecular analysis. Based on GEP ,  specific “tumor profile 
signature for PTCLs” is identified,  which differentiates double positive (CD4+, 
CD8+) from double negative phenotype form of DLB-CL. In both subtypes 
genetic alteration in genes for adhesion and matrix remodeling (FN1<LAMB1, 
COL1A2, COL3A1, COL4A2, and COL12A1) apoptosis (e.g., MOAMP1, ING3, 
GADD45A, and PDGFR alfa) has been identified. In both genomic profiles NF-kB 
pathway is activated, which enables the application of target therapy (Gleevec, 
monoclonal antibody to HGF, STK6, CD52 (Camptah-1H) (65,66). 33 www.onk.ns.ac.yu/Archive   Vol 15,  no 1-2,  July 2007
Review article
In angioimmunoblastic T-cell lymphoma (AITL) is detected molecular profil-
ing with overexpression of B cell and follicular dendritic cell related genes, 
chemokines genes, ECM genes, and overexpression of several genes which 
characterize normal follicular T helper cells (CXC13, Bcl -6, PDCD1, CD4CL, 
NF ATC1) (67). 
Piva R et al., and Lamant L et al. in anaplastic large cell lymphomas (ALKs) 
supervised analysis identified two different gene expression profiles: ALK + 
and ALK – subgroups. The ALKs are characterized by specific chromosomal 
translocation in which the anaplastic lymphoma kinase gene is fused to the 
nucleophosmin gene (68). In ALK+ signature there was significant overex-
pression of Bcl-6, PTP12, CEBPB and SERP1NA1 genes, while in ALK- genes 
CCR7, CNTFR, IL 22, and IL 21 were overexpressed (69).  Systematic screen-
ing of these genes can be used for individual target therapy (68,69). 
Gene expression of chronic lymphocytic 
leukemia      
Chronic lymphocytic leukemia (CLL) is malignant B lymphocytes character-
ized  by  variable  clinical  course  and  overall  survival  ranging  form  several 
months to several decades. Such variability is a consequence of multigenic 
changes. Wang et al., was the first to discover  “CLL signature” from at least 
ten genes (CD23, FGR, TNFRSF1B, CCR7, IL 4R, PPN12, FMOD, TMEM1, 
CHS 1, ZNF266, CDS, IL2RA, Bcl-2, WNT3 and ROR1) that can help to dif-
ferentiate normal B lymphocyte form lymphocyte in CLL  (70). In B CLL, the 
immunoglobulin heavy chain variable region can be mutated or nonmutated. 
CLL patients with unmutated IGVH genes have a much worse overall survival 
(range,  79-119  months)  then  patients  with  mutated  IGVH  genes  (median 
survival up to 293) (Figure 6) (71-73). 
Figure . Overall survival patients with chronic lymphocytic leukemia based on 
IGVH mutation status. The two curves compare CLL patients, one with somatically 
mutations IGVH genes (blue), and other with unmutated IGVH genes (purple). (with 
permission, Staudt LM, et al. Molecular diagnosis of the hematologic cancers. N 
Engl J Med 2003;34:1777-5. Copyright © 2003 Massachusetts Medical Society. 
All rights reserved.)
The BCR stimulation in the IGVH in mutated CLL subtype contributes to the 
more progressive clinical course. A number of biological parameters, IGVH 
mutations,  CD38  and  ZAP-70  expression  in  leukemic  cells  are  important 
independent prognostic markers. The high level expression zeta-associated 
protein-70 (ZAP-70) is the best gene for differentiation in all immunoglobulin 
unmutated CLL (74). Rosenwald study confirmed that ZAP-70 expression 
could predict the IGVH mutation status, but RAF1, PAX5 expressed genes 
may  be  gold  markers  for  differentiating  between  these  groups  and  can 
serve as prognostic markers (75).  ZAP-70 and IGVH mutations have similar 
prognostic information and therefore they can substitute each other. Also, the 
expression of CD38, IL13, IL18, and L-selection is associated with the poor 
prognosis patients with CLL (75). Patients with LPL expression in CLL cells 
have significantly shorter survival time up to 23 months than the patients with 
LPL- expression with survival period of 88 months (76). Buhl AM et al. has 
identified a new disease specific gene CLLUR-1 (CLL upregulated gene-1) 
on chromosome 12q in germinal center B cells in CLL (77). The p53 mutant 
CLL  cells  which  are  fludarabine  resistant  have  aggressive  clinical  course 
and deletion of 11q (ATM gene) and correlates with a lower response rate to 
fludarabine and early response after autologous stem cell transplantation (78). 
About 10% of patients with CLL have mutations in genes for miRNAs. Thirteen 
miRNAs genes were identified in CLL. They represent a unique genetic spe-
cific profiling and could potentially be useful to distinguish between the two 
types (mutation and nonmutation) of CLL (79). The overexpression of miRNA-
21 and miRNA-155 is identified in CLL, but identified in about 11% of CLL 
patients decreased miRNA15a/miRNA-16 and miRNA-146 exists. Thirteen 
out of several hundred miRNAs genes correlate with ZAP-70 expression and 
IGVH mutations status (80,81).
Conclusion
In postgenomic era, microarray technology has been of great help in identi-
fication of molecular heterogeneity of identical histological types of NHL and 
initiation of new genomic classification of this disease. In addition, microarray 
technology has enabled discovery of new and specific genomic expression 
profiles of DLB-CL, FL, BL, MC, T-cell lymphomas, CLL, etc., and helped the 
creation of supervised and unsupervised predictive and prognostic models. 
Genomic  expression  analysis  can  precisely  identify  molecular  variants  of 
DLB-CL, FL, MCL or blastoid variant of this histological type. It can also give 
additional  information  necessary  for  establishing  of  differential  diagnosis 
of  DLB-CL  from  PMBL  and  of  PMBL  from  mediastinal  type  of  Hodgkin 
disease.  Apart  from  these  genomic  signatures,  microarray  analysis  has 
revealed individual genetic markers such as cyclin E, Bcl-2, Bcl-6, CD44v6, 
PDL2,CD68, which are in correlation with disease prognosis. Nowadays, the 
transfer of these basic researching into hematooncological practice is gradual 
and it relies mainly on traditional REAL classification and prognostic indexes.   
Robotization of microarray technology and its limitations in clinical practice 
have initiated the transfer of genomic signatures into the area of immunohis-
tochemical and cytofluorometric detection of prognostic genetic markers. For 
example, immunohistochemical expression of bcl-2, bcl-6 and CD10 can be 
used for identification of DLBCL subgroups as well as with the lymphochip. 
Genomic  researching  and  initial  epigenetic  analyses  have  contributed  to 
better understanding of molecular biology and pathogenesis of lymphoma 
and enabled the development of the concept of individual approach in the 
treatment of certain lymphomas. Further progress in genomic researching of 
lymphomas is directed to the improvement of taxonomy and development of 
individual targeted therapy. 34 www.onk.ns.ac.yu/Archive   Vol 15,  no 1-2,  July 2007
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